Histone deacetylases: A new class of efficient anti-tumor drugs;Les histones désacétylases: Nouvelles cibles pour les thérapies anti-cancéreuses

Medecine/Sciences

Volumn 24, Issue 8-9, 2008, Pages 742-746

  Mottet, Denis ^a   Castronovo, Vincent ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE INHIBITOR;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CELL PROLIFERATION; CHROMATIN; DISEASE COURSE; DRUG EFFICACY; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; HUMAN; NEOPLASM; PHENOTYPE; REVIEW; TREATMENT OUTCOME;

EID: 53049106125     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20082489742     Document Type: Review

References (17)

1. De Ruijter AJ, van Gennip AH, Caron HN, et al. Histone deacetylases (HDACs): characterization of the classicat HDAC family. Biochem J 2003 ; 370 : 737-49.
2. Marks PA, Miller T, Richon VM. Histone deacetylases. Curr Opin Pharmacol 2003 ; 3 : 344-51.
3. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006 ; 5 : 769-84.
4. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007 ; 5 : 981-9.
5. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001 ; 13 : 477-83.
6. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005 ; 96 : 293-304.
7. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002 ; 1 : 287-99.
8. Piekarz RL, Sackett DL, Bates SE. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer J 2007 ; 13 : 30-9.
9. Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 2007 ; 16 : 659-78.
10. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007 ; 26 : 5541-52.
11. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005 ; 363 : 15-23.
12. Magnaghi-Jaulin L, Eot-Houllier G, Fulcrand G, Jaulin C. Histone deacetylase inhibitors induce premature sister chromatid separation and override the mitotic spindle assembly checkpoint. Cancer Res 2007 ; 67 : 6360-7.
13. Qiu JW. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005 ; 102 : 673-8.
14. Ungerstedt JS, Sowa Y, Xu WS, et al. Rote of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005 ; 102 : 673-8.
15. Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 2007 ; 26 : 5489-504.
16. Weber M. Profils de methylation de l'ADN dans les cellules normales et cancéreuses. Med Sci (Paris) 2008 ; 24 : 731-4.
17. Bertin A, Mangenot S. Structure et dynamique de la particule cœur de nucléosome. Med Sci (Paris) 2008 ; 24 : 715-9.